COVID-19 Pipeline Insights, Clinical Trials, Treatment Drugs, and Companies 2024 (Updated)

DelveInsight's, "Covid-19 Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Covid-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in COVID-19 Research. Learn more about our innovative pipeline today! @ COVID-19 Pipeline Outlook- https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the COVID-19 Pipeline Report
• In December 2024:- Novavax- The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313).
• In December 2024:- Gilead Sciences:- The goal of this clinical study is to test if obeldesivir (GS-5245) is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a standard risk of developing severe illness. This study will also measure how much obeldesivir gets into the blood and how long it takes for the body to get rid of it.
• DelveInsight's COVID-19 pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies such as Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Statera Biopharma, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.
• Promising COVID-19 Therapies such as Raloxifene, metenkefalin + tridecactide, Bemnifosbuvir (BEM), TJ003234, and others.

Stay informed about the cutting-edge advancements in COVID-19 Treatments. Download for updates and be a part of the revolution in care @ COVID-19 Clinical Trials Assessment- https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

COVID-19 Emerging Drugs Profile

• DAS181: Ansun Pharm
DAS181 is a recombinant sialidase enzyme that works by removing sialic acids from the lung surface so that influenza cannot bind to infect. This interrupts the virus lifecycle and allows patients the chance to recover. By targeting the host rather than the virus, DAS181 is less susceptible to drug resistant strains of virus, and by targeting the host rather than a specific virus, DAS181 works for other viruses that use sialic acid receptors. DAS181 is delivered in a nebulized formulation using Aerogen Solo aerosol drug delivery technology. The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Breakthrough Therapy Designation to DAS181. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• Sarconeos (BIO101): Biophytis
Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• MP1032: MetrioPharm
MP1032 is a unique small molecule targeting overshooting reactions of activated immune cells by addressing a central, natural metabolic process occurring in activated immune cells. The mitochondria of these cells react to the activation by boosting their energy metabolism, which in turn leads to the generation of reactive oxygen species (ROS) and an increase of intercellular pH. MP1032 is activated only by clusters of elevated pH and acts as an ROS scavenger, normalizing the pathologically increased ROS levels (oxidative stress). Once the pH returns to normal, the drug stops is no longer activated and working. This unique, self-regulating mechanism of action makes MP1032 a first-in-class anti-inflammatory drug that reduces excessive ROS without interfering with the physiological ROS levels of other cells that are essential for normal cell function, resulting in an excellent safety profile. Currently, the drug is in Phase II stage of its development for the treatment of Covid-19.

• GLS-5310: GeneOne Life Science
GLS-5310 is a DNA vaccine encoding the spike (S) protein and a second antigenic target of SARS-CoV-2. StateGLS-5310 is being developed with support from the Government of Korea, through the Centers for Disease Control and Prevention, as part of a national project to develop COVID-19 vaccines. GLS-5310 is in pre-clinical development. Currently, the drug is in Phase I/II stage of its development for the treatment of Covid-19.

• STAT-205: Statera Biopharma
STAT-205 is expected to potentially treat acute and post-acute COVID infections by modulating immune system function and by decreasing elevated inflammatory responses associated with SARS-CoV-2 viral infections, making it a potential candidate for the treatment of Acute and Post-Acute COVID-19. With the FDA having cleared the Investigational New Drug (IND) application, Statera has initiated a clinical trial in acute COVID to evaluate the pharmacokinetics and biomarkers of STAT-205. Preliminary in vitro data have shown to slow or halt the progression of SARS-CoV-2 in human lung cells, the virus that causes COVID-19. Statera is also planning a study evaluating STAT-205 in patients with post-acute COVID-19 syndrome (PACS). Also known as "long haulers," these patients represent a high unmet medical need as roughly 30% of all COVID-19 infections develop into long-haul syndrome. Currently, the drug is in Phase I stage of its development for the treatment of Covid-19.

Learn more about COVID-19 Drugs opportunities in our groundbreaking COVID-19 Research and development projects @ COVID-19 Unmet Needs- https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

COVID-19 Companies
Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Statera Biopharma, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

COVID-19 Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in COVID-19 treatment by visiting our website. Stay informed about how we're transforming the future of disease @ COVID-19 Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the COVID-19 Pipeline Report
• Coverage- Global
• COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Statera Biopharma, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma, and others.
• COVID-19 Therapies- Raloxifene, metenkefalin + tridecactide, Bemnifosbuvir (BEM), TJ003234, and others.
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of COVID-19 Pipeline on our website @ COVID-19 Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. DAS181: Ansun Pharm
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. MP1032: MetrioPharm
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I/II)
13. GLS-5310: GeneOne Life Science
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

List of Top Selling Market Research Reports in 2024

attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
external defibrillators market- https://www.delveinsight.com/report-store/external-defibrillators-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
ornithine transcarbamylase deficiency market- https://www.delveinsight.com/report-store/ornithine-transcarbamylase-deficiency-otc-deficiency-market
pediatric neuroblastoma market- https://www.delveinsight.com/report-store/neuroblastoma-market
schistosomiasis market- https://www.delveinsight.com/report-store/schistosomiasis-market
tcr therapy market- https://www.delveinsight.com/report-store/tcr-therapy-market
uk healthcare report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
vascular access devices market https://www.delveinsight.com/report-store/vascular-access-device-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
artificial disc market- https://www.delveinsight.com/report-store/artificial-disc-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-market
respiratory syncytial virus market- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market
shingles market - https://www.delveinsight.com/report-store/shingles-market
short bowel syndrome drug market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
cxcr inhibitors market- https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
short bowel syndrome market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
carcinoid syndrome market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-market
catheter stabilization devices market- https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
celiac disease market- https://www.delveinsight.com/blog/celiac-disease-market-key-companies
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
pulmonary emphysema market- https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-treatment-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
nk cell therapy market- https://www.delveinsight.com/blog/nk-cell-therapy-in-cancer-treatment
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
healthcare consulting solutions- https://www.delveinsight.com/consulting
skin neoplasm market- https://www.delveinsight.com/report-store/nonmelanoma-skin-cancer-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
meibomian gland dysfunction market- https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight
dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-epidemiology-forecast-insight
testicular neoplasm market- https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
medical marijuana market- https://www.delveinsight.com/blog/medical-marijuana-market
microscopy device market- https://www.delveinsight.com/sample-request/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.